entertainment -WSS

entertainment

author：comprehensive 2025-09-06 01:57:43 - browse：584

MODERNA - Norwood facility — Alex Hogan/STAT

Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses.

The findings, disclosed in a press release, suggest the company may be on track to bring a combination flu and Covid vaccine to the market, potentially as early as autumn 2025.

“We’re excited to move forward in our discussions with regulators, and hopefully continue to help address respiratory viruses globally,” Moderna President Stephen Hoge told STAT in an interview in which he acknowledged that the fall 2025 vaccine rollout is a target the company would like to hit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Can U.S. cancer drug shortages be fixed?

focus

WSS

How the first Native Hawaiian psychiatrist helped diversify medicine

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

How the drug

Walmart eyes Medicare Advantage provider ChenMed

Listen: Vivek Ramaswamy's star turn & leaky drug data

Roche's accidental data boosts hopes for anti

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

Roche's accidental data boosts hopes for anti

After affirmative action ruling, medical educators look to 'holistic review'

Food makers to regulators: Ultra

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA advisory panel to debate high blood pressure devices

Malaria cases in Florida and Texas: Here’s what you need to know

Will the IRA bring competition to the biologics market?

State Dept. review finds Biden bears some blame for Afghanistan failures

Long Covid needs a new name — and a new frame

entertainment

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Generate Biomedicines machine learning biotech raises $273M

Generate Biomedicines machine learning biotech raises $273M

Listen: Vivek Ramaswamy's star turn & leaky drug data

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Former Pear Therapeutics executives start new VC firm

explore

focus

focus

hotspot